Loading patent…
OwnerSusanna Pietropaolo, Wilhelmus Crusio +2inventors
InventorsSusanna Pietropaolo, Wilhelmus Crusio, Valérie Lemaire, Eric Louette
Estimating the term…
The present invention relates to compounds and compositions for use in a method of treating and/or preventing neurological or non-neurological channelopathies, i.e., pathologies which are caused specifically by defects in some of the calcium-activated potassium channels. Specific neurological channelopathies and/or synaptopathies targeted by the present invention include specific neuropsychiatric pathologies, such as particularly Fragile X Syndrome (FXS), Angelman syndrome, Williams-Beuren syndrome, autism, Autism spectrum disorders (ASDs), hyperacusis, Smith-Magenis syndrome, Prader-Willi syndrome, 7q11.23 duplication syndrome, and cri-du-chat syndrome, as well as other neuropathic disorders such as trembling, epilepsy and neuropathic pains associated and neurodegenerative diseases such as Parkinson's and Alzheimer diseases. Compounds, compositions and methods of the present invention are also particularly useful and efficient in alleviating neurological symptoms common to these neuropsychiatric pathologies.
A method of treating neuropsychiatric pathologies in a subject, wherein the neuropsychiatric pathologies consist of Fragile X Syndrome (FXS), Angelman syndrome, Williams-Beuren syndrome, hyperacusis, Smiths-Magenis syndrome, Prader-Willi syndrome, 7q11.23 duplication syndrome, or cri-du-chat syndrome, wherein the method comprises administering to the subject a therapeutically effective amount of a composition comprising an agonist of the large-conductance calcium-activated potassium channel (BKCa channel), and wherein the agonist is chlorzoxazone or acetazolamide.
Dependencies are inferred from the claim text.